Application 075163

Type
ANDA
Sponsor
HI TECH PHARMA

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001TIMOLOL MALEATETIMOLOL MALEATESOLUTION/DROPS;OPHTHALMICEQ 0.5% BASENoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075163-001TIMOLOL MALEATETIMOLOL MALEATEEQ 0.5% BASESOLUTION/DROPS / OPHTHALMIC2002-09-10

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Timolol MaleateTIMOLOL MALEATEOceanside Pharmaceuticals3c20b537-88c6-4ec7-a359-e0ba67afe4312026-04-20Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATESagent Pharmaceuticals272bb565-f099-4896-b2f6-48ab9180e9412026-01-09Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEA-S Medication Solutions7a1ea848-5b55-4038-afb1-029645ee09252025-12-30Warnings, Adverse reactionsName fallback
Timolol maleateTIMOLOL MALEATEArmas Pharmaceuticals, Inc.ea585fe8-3356-4f08-8078-34e8ab5de37e2025-12-03Warnings, Adverse reactionsName fallback
TIMOLOL MALEATETIMOLOL MALEATERising Pharma Holdings, Inc.2ed21930-1e05-46de-8acd-cb6f4798a7fa2025-05-09Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEBausch & Lomb Americas Inc.581f80f7-4419-49e2-867d-40443c75409f2025-03-26Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEBausch & Lomb Americas Inc.036dc753-1698-4c69-9bcf-752c7061203c2025-03-05Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEBausch & Lomb Americas Inc.9c14ca2d-80f3-48ef-b99a-beafaa728a242025-03-04Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEA-S Medication Solutions5305a38e-d9c8-4f9e-bf67-b246abc82cb12024-12-20Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEMicro Labs Limited79b223e4-d929-4667-8149-e79bfab13fdf2024-12-05Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATEBausch & Lomb Americas Inc.b686bbad-1ef7-4b94-a316-4d182a40b89a2024-11-04Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATESomerset Therapeutics, LLCe797f7c7-0588-4627-b060-8df6bcfe3f7b2024-10-31Warnings, Adverse reactionsName fallback
TIMOLOL MALEATETIMOLOL MALEATELeading Pharma, LLCd6fa2971-dacf-42ab-99bc-c7ce6013221e2024-10-30Warnings, Adverse reactionsName fallback
timolol maleateTIMOLOL MALEATENorthStar RxLLC9db7322d-eb31-4fff-9b14-8a0294d017042024-10-14Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATE OPHTHALMICMicro Labs Limited6c9f3971-8c07-4d3a-915d-76438baa2a0b2024-10-03Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATECaplin Steriles Limited4847f180-45e6-40f0-ae8c-6cc500cb0add2024-08-19Warnings, Adverse reactionsName fallback
Timolol maleateTIMOLOL MALEATESomerset Therapeutics, LLC5d60db57-ca24-4cab-a90d-8cf06992a34e2024-07-04Warnings, Adverse reactionsName fallback
Timolol MaleateTIMOLOL MALEATERising Pharma Holdings, Inc.0bc40b2c-65eb-4095-87e6-4752d5b19a3a2024-06-11Warnings, Adverse reactionsName fallback
TIMOLOL MALEATETIMOLOL MALEATEA-S Medication Solutions1ffd9ed1-8ab4-4036-bbc6-dcf58e6592482024-06-03Warnings, Adverse reactionsName fallback
TIMOLOL MALEATETIMOLOL MALEATEAurobindo Pharma Limitede6c74f66-ee84-4bcc-b1da-b8e6ff240dd22024-05-16Warnings, Adverse reactionsName fallback

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Potentiation of Respiratory Reactions Including Asthma ( 5.1 ) Cardiac Failure ( 5.2 ) Obstructive Pulmonary Disease ( 5.3 ) Increased Reactivity to Allergens ( 5.4 ) Potentiation of Muscle Weakness ( 5.5 ) Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus ( 5.6 ) Masking of Thyrotoxicosis ( 5.7 ) 5.1 Potentiation of Respiratory Reactions Including Asthma Timolol Maleate Ophthalmic Solution 0.5% contains timolol maleate; and although administered topically, it can be absorbed systemically. Therefore, the same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see Contraindications ( 4.1 )]. 5.2 Cardiac Failure Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Timolol Maleate Ophthalmic Solution 0.5% should be discontinued [see Contraindications ( 4.2 )]. 5.3 Obstructive Pulmonary Disease Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease [other than bronchial asthma or a history of bronchial asthma in which Timolol Maleate Ophthalmic Solution 0.5% is contraindicated] should, in general, not receive beta-blocking agents, including Timolol Maleate Ophthalmic Solution 0.5% [see Contraindications ( 4.1 )]. 5.4 Increased Reactivity to Allergens While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat...

warnings and cautions

5.1 Potentiation of Respiratory Reactions Including Asthma Timolol Maleate Ophthalmic Solution 0.5% contains timolol maleate; and although administered topically, it can be absorbed systemically. Therefore, the same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see Contraindications ( 4.1 )].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The most frequently reported adverse reactions have been burning and stinging upon instillation in 38% of patients treated with Timolol Maleate Ophthalmic Solution 0.5%. Additional reactions reported with Timolol Maleate Ophthalmic Solution 0.5% at a frequency of 4 to 10% include: blurred vision, cataract, conjunctival injection, headache, hypertension, infection, itching and decreased visual acuity . ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions have been burning and stinging upon instillation in 38% of patients treated with Timolol Maleate Ophthalmic Solution 0.5%. Additional reactions reported with Timolol Maleate Ophthalmic Solution 0.5% at a frequency of 4 to 10% include: blurred vision, cataract, conjunctival injection, headache, hypertension, infection, itching and decreased visual acuity. The following additional adverse reactions have been reported less frequently with ocular administration of this or other timolol maleate formulations. Timolol (Ocular Administration) Body as a Whole: Asthenia/fatigue and chest pain; Cardiovascular: Bradycardia, arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud’s phenomenon and cold hands and feet; Digestive: Nausea, diarrhea, dyspepsia, anorexia, and dry mouth; Immunologic: Systemic lupus erythematosus; Nervous System/Psychiatric: Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness and memory loss; Skin: Alopecia and psoriasiform rash or exacerbation of psoriasis; Hypersensitivity: Signs and symptoms of systemic allergic reactions, including angioedema, urticaria, and localized and generalized rash; Respirator...

adverse reactions

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported adverse reactions have been burning and stinging upon instillation in 38% of patients treated with Timolol Maleate Ophthalmic Solution 0.5%. Additional reactions reported with Timolol Maleate Ophthalmic Solution 0.5% at a frequency of 4 to 10% include: blurred vision, cataract, conjunctival injection, headache, hypertension, infection, itching and decreased visual acuity. The following additional adverse reactions have been reported less frequently with ocular administration of this or other timolol maleate formulations. Timolol (Ocular Administration) Body as a Whole: Asthenia/fatigue and chest pain; Cardiovascular: Bradycardia, arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud’s phenomenon and cold hands and feet; Digestive: Nausea, diarrhea, dyspepsia, anorexia, and dry mouth; Immunologic: Systemic lupus erythematosus; Nervous System/Psychiatric: Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness and memory loss; Skin: Alopecia and psoriasiform rash or exacerbation of psoriasis; Hypersensitivity: Signs and symptoms of systemic allergic reactions, including angioedema, urticaria, and localized and generalized rash; Respiratory: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections; Endocrine: Masked symptoms of hypoglycemia in diabetic patients [see Warnings and Precautions ( 5.6 )]; Special Senses: Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis, decreased corneal sensitivity; cystoid macular edema; visual disturbances includ...

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50383-021Timolol MaleateTimolol MaleateAkornANDACurrent
50383-021Timolol MaleateTimolol MaleateHi-Tech Pharmacal Co., Inc.ANDACurrent
50383-021Timolol MaleateTimolol MaleateHi-Tech Pharmacal Co., Inc.ANDACurrent